Exelixis
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United St...
Latest News
9 hours ago · fool.com
Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change EverythingCabometyx's sales keep growing, but generic competition looms by the end of the decade. Meanwhile, zanzalintinib could earn approval by March of 2027.
3 days ago · fool.com
Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch.Exelixis' cabozantinib, addressing various types of cancer, has driven tremendous growth over the past 10 years. The company is now betting on a next-generation candidate that's approaching the finish line.
5 days ago · marketbeat.com
Exelixis Nears FDA Decision, Key Kidney Cancer Data for ZanzalintinibExelixis NASDAQ: EXEL is preparing for a regulatory decision on its cancer drug candidate zanzalintinib and expects results from a kidney cancer study in the first quarter of next year, Chief Strategy Officer Andrew Peters said at an investor event.
5 days ago · seekingalpha.com
Exelixis, Inc. (EXEL) Presents at Stifel 2026 Healthcare Conference 2026 TranscriptExelixis, Inc. (EXEL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
6 days ago · marketbeat.com
Exelixis Bets on Zanza as Next Cancer Franchise as FDA Decision NearsExelixis NASDAQ: EXEL is working to build its next cancer drug franchise around zanzalintinib, or zanza, while continuing to grow its established CABO business, Chief Strategy Officer Andrew Peters said at a conference discussion with Guggenheim biotech analyst Michael Schmidt.
6 days ago · seekingalpha.com
Exelixis, Inc. (EXEL) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference TranscriptExelixis, Inc. (EXEL) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
8 days ago · zacks.com
Here's Why Exelixis (EXEL) is a Strong Growth StockWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
15 days ago · zacks.com
Exelixis (EXEL) International Revenue in Focus: Trends and ExpectationsEvaluate Exelixis' (EXEL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
18 days ago · zacks.com
EXEL Q3 Earnings Beat Estimates on Strong Cabometyx SalesExelixis tops Q3 2026 earnings and revenue estimates as Cabometyx sales grow, share repurchases accelerate and its zanzalintinib pipeline advances.
18 days ago · seekingalpha.com
Exelixis, Inc. (EXEL) Q3 2026 Earnings Call TranscriptExelixis, Inc. (EXEL) Q3 2026 Earnings Call Transcript
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove EXEL